Latest stories on COAG
Hemab Therapeutics initiated with an Overweight at JPMorgan
The Fly63 · neutralanalyst
JPMorgan initiates Hemab Therapeutics stock with overweight rating
Investing.com Analyst Ratings63 · neutralanalyst
Hemab Therapeutics initiated with a Buy at Rodman & Renshaw
The Fly63 · neutralanalyst
Hemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung Ladder
Seeking Alpha58 · neutralgeneral
Hemab Therapeutics Holdings, Inc. (COAG) files 8-K
SEC 8-K50 · neutralgeneral
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
GlobeNewswire59 · neutralgeneral
COAG advances HMB-003 into Phase 1 with once-per-cycle dosing potential for heavy menstrual bleeding
September 18, 2026
MarketChameleon63 · neutralproduct/pr
Hemab Therapeutics doses first patient in HMB-003 trial
The Fly56 · neutralproduct/pr
Hemab Therapeutics price target raised to $64 from $55 at Wedbush
The Fly61 · neutralanalyst
Hemab Therapeutics price target raised to $60 from $52 at H.C. Wainwright
The Fly63 · neutralanalyst
Hemab Therapeutics Reports Q2 Eps 80c Consensus 82c
The Fly48 · neutralearnings
Hemab Therapeutics Holdings, Inc. (COAG) files 8-K
SEC 8-K50 · neutralgeneral
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Business Insider55 · neutralgeneral
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | COAG Stock News
StockTitan56 · neutralgeneral
Hemab Therapeutics Holdings, Inc. GAAP EPS of -$23.98
Seeking Alpha28 · bearishearnings
Hemab Therapeutics Reports First Quarter 2026 Financial Results | COAG Stock News
StockTitan67 · bullishearnings